FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105130942> ?p ?o ?g. }

• W2105130942 endingPage "428" @default.
• W2105130942 startingPage "428" @default.
• W2105130942 abstract "We read with interest two case reports of fatal thrombotic complications after cardiopulmonary bypass.1,2However, there are several unclear issues that the readers should become aware of. First, it is not clear whether adequate heparin levels were maintained during cardiopulmonary bypass (CPB) because activated clotting time (greater than 400–600 s*) does not necessarily reflect the efficacy of heparin anticoagulation.3Heparin insensitivity due to antithrombin deficiency may be masked by thrombocytopenia, hypofibrinogenemia, or other coagulation factor defects. At our institution, we administer hourly bolus doses of 100 U/kg heparin during CPB to prevent the decrease of plasma heparin levels. Furthermore, we frequently replete antithrombin during prolonged CPB (approximately 3 h) in suspected antithrombin-deficient cases by adding fresh frozen plasma or antithrombin concentrate (Thrombate III®; Talecris Biotherapeutics, Research Triangle Park, NC). We have previously shown that reduced antithrombin levels greatly enhance the rate and peak level of thrombin generation.4In patients with endocarditis, prolonged CPB, or both, plasma antithrombin levels may become critically low.5Intravascular fluidity, however, may be maintained by the balance between low procoagulant (fibrinogen, platelet) and low anticoagulant levels (antithrombin, protein C and S, thrombomodulin). Under such conditions consistent with disseminated intravascular coagulopathy, one may observe bleeding tendency. In both cases that the authors described, the administration of hemostatic blood products, platelet concentrate,1and cryoprecipitate2after heparin reversal seemed to have triggered thrombotic complications. Rapid extensions of thrombi suggest that uncontrolled “thrombin generation” occurred, and it is questionable whether thrombi could have been quickly dissolved by endogenous fibrinolytic system even in the absence of aprotinin or other antifibrinolytic agents.6In the case of afibrinogenemia referenced by the authors, it is possible that normal anticoagulant function and short CPB time (36 min) limited thrombus formation locally (i.e. , graft occlusion) without systemic thrombus extension.7To further stress the importance of adequate anticoagulation, the incidence of deep venous thromboses does not seem to be increased with intraoperative use of aprotinin in the orthopedic surgery when prophylaxis for deep venous thromboses (e.g. , low-molecular-weight heparin) is implemented.8These two catastrophic cases highlight the importance of balancing procoagulant and anticoagulant components of coagulation to achieve localized hemostasis while avoiding thrombotic complications. Further clinical trials must be conducted to improve our current anticoagulant strategy.9†Emory University School of Medicine, Atlanta, Georgia. kenichi.tanaka@emoryhealthcare.org" @default.
• W2105130942 created "2016-06-24" @default.
• W2105130942 creator A5008806595 @default.
• W2105130942 creator A5049844818 @default.
• W2105130942 date "2006-08-01" @default.
• W2105130942 modified "2023-10-16" @default.
• W2105130942 title "Systemic Thromboses after Cardiopulmonary Bypass: Is It Thrombin or Antithrombin?" @default.
• W2105130942 doi "https://doi.org/10.1097/00000542-200608000-00030" @default.
• W2105130942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16871082" @default.
• W2105130942 hasPublicationYear "2006" @default.
• W2105130942 type Work @default.
• W2105130942 sameAs 2105130942 @default.
• W2105130942 citedByCount "8" @default.
• W2105130942 countsByYear W21051309422017 @default.
• W2105130942 crossrefType "journal-article" @default.
• W2105130942 hasAuthorship W2105130942A5008806595 @default.
• W2105130942 hasAuthorship W2105130942A5049844818 @default.
• W2105130942 hasBestOaLocation W21051309421 @default.
• W2105130942 hasConcept C126322002 @default.
• W2105130942 hasConcept C164705383 @default.
• W2105130942 hasConcept C2777292125 @default.
• W2105130942 hasConcept C2777557582 @default.
• W2105130942 hasConcept C2778881276 @default.
• W2105130942 hasConcept C2779026020 @default.
• W2105130942 hasConcept C3018972837 @default.
• W2105130942 hasConcept C42219234 @default.
• W2105130942 hasConcept C71924100 @default.
• W2105130942 hasConcept C89560881 @default.
• W2105130942 hasConceptScore W2105130942C126322002 @default.
• W2105130942 hasConceptScore W2105130942C164705383 @default.
• W2105130942 hasConceptScore W2105130942C2777292125 @default.
• W2105130942 hasConceptScore W2105130942C2777557582 @default.
• W2105130942 hasConceptScore W2105130942C2778881276 @default.
• W2105130942 hasConceptScore W2105130942C2779026020 @default.
• W2105130942 hasConceptScore W2105130942C3018972837 @default.
• W2105130942 hasConceptScore W2105130942C42219234 @default.
• W2105130942 hasConceptScore W2105130942C71924100 @default.
• W2105130942 hasConceptScore W2105130942C89560881 @default.
• W2105130942 hasIssue "2" @default.
• W2105130942 hasLocation W21051309421 @default.
• W2105130942 hasLocation W21051309422 @default.
• W2105130942 hasOpenAccess W2105130942 @default.
• W2105130942 hasPrimaryLocation W21051309421 @default.
• W2105130942 hasRelatedWork W140142063 @default.
• W2105130942 hasRelatedWork W204743721 @default.
• W2105130942 hasRelatedWork W2048676023 @default.
• W2105130942 hasRelatedWork W2078486773 @default.
• W2105130942 hasRelatedWork W2079862910 @default.
• W2105130942 hasRelatedWork W2093821740 @default.
• W2105130942 hasRelatedWork W2129730153 @default.
• W2105130942 hasRelatedWork W2409473041 @default.
• W2105130942 hasRelatedWork W4251693991 @default.
• W2105130942 hasRelatedWork W4255940571 @default.
• W2105130942 hasVolume "105" @default.
• W2105130942 isParatext "false" @default.
• W2105130942 isRetracted "false" @default.
• W2105130942 magId "2105130942" @default.
• W2105130942 workType "article" @default.